ArticleBMJ open2020

Protocol for a phase IV, open-label feasibility study investigating non-invasive markers of hepatic fibrosis in people living with HIV-1 and non-alcoholic fatty liver disease randomised to receiving optimised background therapy (OBT) plus maraviroc or OBT alone.

Daniel Bradshaw et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.